Description
ATOSTRATT 40 CAP is a specialized medication formulated with Atomoxetine Hydrochloride 40 mg, designed for the management of Attention Deficit Hyperactivity Disorder (ADHD). As a non-stimulant, Atomoxetine offers a reliable and well-tolerated alternative to traditional stimulant-based ADHD therapies like methylphenidate or amphetamines.
Atomoxetine acts by selectively inhibiting the presynaptic norepinephrine transporter, increasing norepinephrine levels in the prefrontal cortex. This enhanced neurotransmitter activity improves attention span, decreases hyperactivity, and reduces impulsiveness—helping individuals manage ADHD symptoms effectively.
ADHD in children (6 years and older)
ADHD in adolescents and adults
Can be prescribed for patients who cannot tolerate stimulant medications
Off-label use in conditions like depression with executive dysfunction (physician-directed)
Atomoxetine increases norepinephrine levels by blocking its reuptake, thereby improving communication between brain cells in regions associated with focus, self-regulation, and behavior control. Unlike stimulants, Atomoxetine is not addictive and has a gradual onset of action.
Non-stimulant ADHD medication
Long-acting, once-daily dosing
No known risk of abuse or dependence
Well-tolerated for long-term use
Can be used in individuals with substance abuse history or cardiac risks
Typically initiated at 40 mg per day
Dose may be adjusted to 80–100 mg daily based on patient response
Administered once or twice daily with or without food
Therapeutic effects may take 1–2 weeks to become noticeable
Dry mouth, decreased appetite, nausea
Fatigue, dizziness, mood swings
Sleep disturbances or sexual side effects (in adults)
Rare: Liver enzyme elevation, suicidal ideation (requires close monitoring)
Regular monitoring in pediatric and adolescent patients for growth, mood changes, and cardiovascular status
Liver function tests recommended in prolonged therapy
Contraindicated in patients with narrow-angle glaucoma or severe cardiovascular disorders
Use with caution in patients taking MAO inhibitors (contraindicated within 14 days)
ATOSTRATT 40 CAP is proudly manufactured and globally distributed by Bluepill Express, a leading Indian pharmaceutical company known for its dedication to third-party manufacturing, private labeling, and international exports.
Bluepill Express operates under the highest standards of WHO-GMP, ISO certification, and stringent regulatory compliance, ensuring the safe and consistent supply of quality pharmaceutical products to markets including:
Asia and Southeast Asia
Africa and the Middle East
Latin America
CIS Countries
Europe, UK, and Australia
Custom branding and contract manufacturing for Atomoxetine
Flexible batch sizes with prompt delivery
Export documentation support (COA, MSDS, COPP, FSC, etc.)
Competitive pricing with bulk order capabilities
